Novo Nordisk weight-loss drug trial

#PRESS: At #ADA2025, Novo Nordisk is sharing the full phase 3 study results in people with overweigh or obesity, and overweight or obesity and type 2 diabetes respectively. Both studies simultaneously published in The New England Journal of Medicine. Read the full press release

P3 CagriSema in adults with overweight #obesity Placebo subtracted #weightloss of 17.3%; 60.2% & 40.4% achieved 20% and 25% weight loss, respectively @AmDiabetesAssn #ADA2025 www.nejm.org/doi/full/10.1056/NEJMoa2502081

Novo Nordisk’s next-gen obesity drug results a letdown for investors, but not physicians, ⁦@elaineywchen⁩ writes. www.statnews.com/2025/06/22/novo-nordisk-cagrisema-weight-loss-drug-comparison-eli-lilly-zepbound-investors-disappointed/

Over the weekend, Novo Nordisk dropped a pile of scientific data on three new experimental weight-loss drugs, including an oral one, showing what appears to be a strategic "something for everyone" plan of attack from the pharmaceutical giant. newatlas.com/disease/obesity/ozempic-novo-nordisk-trial/ pic.x.com/CnvaOPRdbl